8-K
filed January 5, 2024, 6:59 PM ET
ticker CHRN
CIK 0001549084
earnings
confidence high
sentiment positive
materiality 0.60
Ekso Bionics prelim Q4 rev ~$4.8M (+31% YoY); FY rev ~$18.2M (+41% YoY); cash $8.6M
EKSO BIONICS HOLDINGS, INC.
2023-FY EPS reported
-$1.10
revenue$18,279,000
- Q4 2023 revenue estimated $4.7-4.9M, up from $3.6M in Q4 2022 (30-36% YoY increase).
- FY 2023 revenue estimated $18.1-18.3M, up from $12.9M in FY 2022 (40-42% YoY increase).
- Cash at Dec 31, 2023 estimated $8.6M vs $20.5M a year ago; Q4 cash burn improved to $1.7M from $3.6M.
- CEO cited strong demand for EksoNR and Indego; final results expected in March 2024.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
EKSO BIONICS HOLDINGS, INC. reported the fiscal year ended December 31, 2023 results: revenue in the range of $18.1 million to $18.3 million.
- Period
- the fiscal year ended December 31, 2023
- Revenue
- in the range of $18.1 million to $18.3 million
- Result
- preliminary results
Exact text from the filing
Total revenue for fiscal year 2023 is estimated to be in the range of $18.1 million to $18.3 million
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
EKSO BIONICS HOLDINGS, INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue in the range of $4.7 million to $4.9 million.
- Period
- the fourth quarter and fiscal year ended December 31, 2023
- Revenue
- in the range of $4.7 million to $4.9 million
- Result
- preliminary results
Exact text from the filing
Total revenue for the fourth quarter of 2023 is estimated to be in the range of $4.7 million to $4.9 million
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.